Subscribe To

Price Alert Latest News Economic Calendar News

PHIO / PHIO Jumps 91% on Encouraging Preclinical Cancer Drug Data

Data from preclinical studies show that Phio's (PHIO) cancer drug PH-894 is effective in BRD4 inhibition for treating various cancer indications like melanoma, breast cancer and lung cancer. Read More

Demo Live Account See Partner Details

Content Topics

PHIO

Jumps

Encouraging

Preclinical

Cancer

Drug

Data

Stock

Posted: Oct 12 2023, 12:47

Author Name: Zacks Investment Research

PHIO News

By Zacks Investment Research
October 12, 2023

PHIO Jumps 91% on Encouraging Preclinical Cancer Drug Data

Data from preclinical studies show that Phio's (PHIO) cancer drug PH-894 is effective in BRD4 inhibition for treating various cancer indications like

By InvestorPlace
October 12, 2023

Why Is Phio Pharma (PHIO) Stock Down 35% Today?

Phio Pharma (NASDAQ: PHIO ) stock is pulling back on Thursday after the immuno-oncology therapeutics company's shares underwent a major rally yesterd

By Zacks Investment Research
May 17, 2023

PHIO's Skin Cancer Candidate to Enter Clinical Study, Stock Up

PHIO surges on the FDA clearance of investigational new drug application for its lead product, PH-762, for the treatment of skin carcinomas.

By InvestorPlace
April 18, 2023

Why Is PHIO Stock Down 20% Today?

It's been a big day for investors in Phio Pharmaceuticals (NASDAQ: PHIO ), unfortunately on the downside. This afternoon, PHIO stock has declined ne

By Benzinga
April 8, 2022

Phio Pharma Shares Shine After Positive PH-894 Preclinical Data At AACR Presentation

Phio Pharmaceuticals Corp (NASDAQ: PHIO) has presented new preclinical data for PH-894, a self-delivering RNAi compound targeting the bromodomain-c

Risk Disclosure:

Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
We would like to remind you that the data contained in this website is not necessarily real-time nor accurate.
The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. We and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of us and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. We may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.